Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01254877 · ClinicalTrials.gov registry record · Phase 2
Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 357
- Enrollment target
NCT01254877: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT01254877 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 357 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01254877, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 357 participants
- Enrollment target
Study Summary
The proposed randomized clinical trial will investigate a novel pharmacotherapy for hazardous drinking, HIV-infected men and women, using the serotonin receptor (5-HT3) antagonist ondansetron. The investigators predict that participants who are treated with active doses of ondansetron will reduce their drinking more and show better HIV treatment participation and progress compared to participants who are treated with placebo. This study will provide important new safety and efficacy results on drinking and HIV outcomes following alcohol pharmacotherapy in HIV-infected persons.
Interventions
- DRUG Ondansetron
- DRUG ondansetron
- DRUG placebo ondansetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2010-12 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01254877
The ClinicalTrials.gov registry entry for NCT01254877 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 357 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ondansetron is the first listed.
NCT01254877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01254877 about?
NCT01254877 is a clinical study titled "Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons". The proposed randomized clinical trial will investigate a novel pharmacotherapy for hazardous drinking, HIV-infected men and women, using the serotonin receptor (5-HT3) antagonist ondansetron. The investigators predict that participants who are treated with active doses of ondansetron will reduce th...
What is the current status of trial NCT01254877?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 357 participants. The study started on 2010-12. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01254877?
The interventions under investigation include: Ondansetron (DRUG), ondansetron (DRUG), placebo ondansetron (DRUG).
Who is sponsoring clinical trial NCT01254877?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.